原发性乳腺恶性淋巴瘤28例

[目的]探讨原发性乳腺恶性淋巴瘤(PBL)的临床病理特点、诊治方法.[方法]回顾性分析28例原发性乳腺恶性淋巴瘤临床资料,中位年龄46岁(30～70岁).按照Ann Arbor分期标准,Ⅰ EA期14例,ⅡEA期8例,ⅢEA期3例,ⅢEB期l例,ⅣEA期2例;其中B细胞来源25例,外周T细胞来源3例.治疗情况:单纯手术组2例,单纯化疗组2例,综合治疗组24例;化疗一般采用CHOP方案,4～8个周期.[结果]随访时间6～139个月,中位随访时间62.5个月,全组患者中位生存时间为66个月(95％CI:50～84),5年生存率为45.6％.[结论]PBL病理以B细胞来源最常见.目前多选择化疗及放疗为基础结合手术的综合治疗,但仍有待多中心随机对照研究加以证实.

Primary Breast Lymphoma: a Clinical Analysis of 28 Cases

[Purpose] To explore the clinicopathologic features and the treatment for primary breast lymphoma(PBL).[Methods] The clinical data of 28 cases with PBL were analyzed retrospectively.Of the 28 cases with PBL,median age at diagnosis was 46 years old.According to the Ann Arbor staging standard,14 cases were stage ⅠEA;8,ⅡE;3,ⅢEA;1,ⅢEB ;and 2,ⅣEA.According to the WHO 2001 lymphoma classification system,25 cases were B-cell lymphoma.Two cases underwent surgery alone while 2 cases received chemotherapy alone,24 cases received combined treatment.The chemotherapy regimen used was CHOP for an average of 4～8 cycles.[Results] The median follow-up peroid was 62.5 months(ranging from 6～139 months).The median survival was 66 months(95%CI:50～84).The 5-year overall survival(OS) rate was 46.5%.[Conclusions] PBL’s main pathological subtype is large B-cell lymphoma.At present,chemotherapy or radiotherapy combined with surgery are the most common choice.A multi-center controlled randomized clinical trial should be pursued to confirm these observations.